GlassScriptPhysician profile
Thomas Krummenacher
NPI 1205837978
$2,039.42
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $425 · 2020: $176 · 2021: $68.32 · 2022: $143 · 2023: $420 · 2024: $807.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,227.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,226.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $466.91 | 2021-2024 | Vabysmo |
| Astellas Pharma US INC | $339.83 | 2023-2024 | Izervay |
| Regeneron Healthcare Solutions, INC. | $219.61 | 2019-2024 | Eylea Hd |
| Novartis Pharmaceuticals Corporation | $208.37 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $157.17 | 2019-2021 | |
| Genentech, INC. | $141.15 | 2024 | Vabysmo |
| Carl Zeiss Meditec, INC. | $131.22 | 2019-2020 | |
| Bausch & Lomb Americas INC. | $126.75 | 2022 | |
| Regeneron Pharmaceuticals, INC. | $118.73 | 2023 | Eylea |
| Allergan, INC. | $39.24 | 2019-2021 | |
| Abbvie INC. | $37.63 | 2023-2024 | |
| Aerie Pharmaceuticals, INC. | $19.70 | 2021 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Eyepoint US, INC. | $13.71 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Krummenacher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.